세계의 소화기 치료제 시장

Global Gastrointestinal Therapeutics Market to Reach US$99.2 Billion by 2030

The global market for Gastrointestinal Therapeutics estimated at US$73.4 Billion in the year 2024, is expected to reach US$99.2 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Crohn's Disease End-Use, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$19.0 Billion by the end of the analysis period. Growth in the Ulcerative Colitis End-Use segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.1 Billion While China is Forecast to Grow at 7.9% CAGR

The Gastrointestinal Therapeutics market in the U.S. is estimated at US$19.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$22.2 Billion by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Gastrointestinal Therapeutics Market - Key Trends and Drivers Summarized

Why Are Gastrointestinal Therapeutics Essential for Modern Healthcare?

Gastrointestinal (GI) therapeutics have become critical in modern healthcare due to their role in managing a wide range of digestive disorders, which affect millions of people globally. These therapies are designed to treat conditions like inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), ulcers, and colorectal cancer, among others. But why are GI therapeutics so essential in today's medical landscape? Gastrointestinal diseases can significantly impact a person’s quality of life, causing pain, discomfort, malnutrition, and even life-threatening complications if left untreated. With the rising prevalence of chronic GI conditions driven by factors like diet, stress, genetics, and aging populations, the demand for effective therapies has never been higher.

GI therapeutics include a broad spectrum of treatments ranging from medications to biologics and surgical interventions. For example, proton pump inhibitors (PPIs) are commonly used to manage acid-related disorders like GERD, while immunosuppressive drugs and biologics are crucial for managing autoimmune diseases like Crohn’s disease and ulcerative colitis. The development of new therapeutics has significantly improved disease outcomes, reducing symptoms, preventing disease progression, and, in some cases, leading to remission. Given the chronic nature of many GI disorders, effective therapeutics are essential for managing symptoms, improving patient quality of life, and reducing the long-term complications associated with these conditions.

How Are Technological Advancements Revolutionizing Gastrointestinal Therapeutics?

Technological advancements are reshaping the field of gastrointestinal therapeutics, leading to more targeted, personalized, and effective treatments. One of the most transformative developments is the rise of biologic therapies. These are complex molecules, such as monoclonal antibodies, designed to target specific components of the immune system that drive inflammation in diseases like Crohn's disease and ulcerative colitis. Unlike traditional medications that suppress the immune system broadly, biologics target specific pathways, reducing inflammation with fewer side effects. Biologics have revolutionized the treatment of autoimmune gastrointestinal disorders, providing patients with longer periods of remission and reducing the need for surgery.

Gene therapy is another promising area of advancement. Research into gene-editing technologies like CRISPR has the potential to treat genetic gastrointestinal disorders by correcting mutations that lead to diseases such as cystic fibrosis or hereditary gastrointestinal cancers. Additionally, microbiome-based therapies are emerging as a novel treatment avenue. Since the gut microbiome plays a crucial role in maintaining digestive health, manipulating the balance of gut bacteria through probiotics, prebiotics, or even fecal microbiota transplants (FMT) offers a new way to treat conditions like IBS, IBD, and Clostridium difficile infections.

Furthermore, advancements in diagnostic technologies, such as capsule endoscopy and genetic testing, are improving the ability to detect GI disorders early and tailor treatments to individual patients. These personalized treatment approaches ensure that patients receive the most effective therapies based on their unique genetic and physiological makeup. Collectively, these innovations are leading to a new era of gastrointestinal therapeutics, where treatments are more precise, effective, and tailored to the specific needs of each patient.

Why Are Gastrointestinal Therapeutics Crucial for Managing Chronic Conditions?

The rising prevalence of chronic gastrointestinal conditions is one of the main reasons why gastrointestinal therapeutics are becoming increasingly important in healthcare. Conditions like Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS) are long-term illnesses that require ongoing management. Patients with these diseases often experience a wide range of symptoms, including abdominal pain, diarrhea, fatigue, and malnutrition, all of which can severely impact their quality of life. GI therapeutics play a crucial role in managing these symptoms, preventing disease progression, and minimizing complications, allowing patients to live healthier and more fulfilling lives.

For chronic conditions like inflammatory bowel disease (IBD), which includes Crohn's and ulcerative colitis, treatments focus on reducing inflammation and maintaining remission. Medications such as corticosteroids, immunosuppressants, and biologics are often used in combination to control flare-ups and prevent long-term damage to the gastrointestinal tract. In recent years, biologic therapies have transformed the management of IBD by providing more targeted and long-lasting relief compared to traditional treatments. These therapies block specific proteins that trigger inflammation, helping to reduce the need for surgery and hospitalizations.

Gastrointestinal therapeutics are also essential in the management of gastroesophageal reflux disease (GERD), a chronic condition where stomach acid frequently flows back into the esophagus, causing heartburn and other symptoms. If left untreated, GERD can lead to complications like esophagitis, Barrett's esophagus, or esophageal cancer. Medications like proton pump inhibitors (PPIs) and H2 receptor antagonists are commonly used to reduce stomach acid production and prevent damage to the esophagus. For patients with chronic, severe GERD, surgical interventions such as fundoplication may also be considered.

In addition to managing symptoms, gastrointestinal therapeutics are essential for preventing complications and improving long-term health outcomes in patients with chronic conditions. These treatments allow patients to achieve better disease control, reducing the burden of symptoms and improving overall quality of life.

What Factors Are Driving the Growth of the Gastrointestinal Therapeutics Market?

The growth of the gastrointestinal therapeutics market is driven by several key factors, including the increasing prevalence of GI disorders, rising demand for biologic therapies, and advancements in precision medicine. First, the global rise in gastrointestinal diseases, particularly chronic conditions like Crohn’s disease, ulcerative colitis, and GERD, is a major driver of market growth. Lifestyle factors such as poor diet, stress, and sedentary behavior are contributing to the increase in digestive disorders, and aging populations are more prone to conditions like colorectal cancer and diverticulitis. As the number of people affected by these conditions grows, the demand for effective therapeutic options is also rising.

Second, the growing adoption of biologic therapies is driving significant growth in the gastrointestinal therapeutics market. Biologics, which include monoclonal antibodies and other targeted therapies, have shown remarkable efficacy in treating inflammatory bowel diseases (IBD) and other immune-mediated conditions. These therapies are often used when traditional medications fail to provide adequate symptom control, making them a preferred option for many patients. The development of biosimilars-affordable alternatives to biologics-is further expanding access to these treatments, increasing market penetration.

Third, advancements in personalized medicine and precision therapeutics are transforming the gastrointestinal treatment landscape. Genetic testing, biomarker discovery, and microbiome analysis are enabling more tailored approaches to GI care. Patients can now receive therapies based on their individual genetic makeup or microbiome profile, leading to better outcomes and fewer side effects. This trend toward personalized medicine is increasing the demand for more targeted and innovative therapies, driving market growth.

Additionally, the rise in minimally invasive treatment options and the development of new drug delivery methods are further boosting the market. For example, capsule endoscopy and targeted drug delivery systems are improving the diagnosis and treatment of gastrointestinal conditions, reducing the need for invasive procedures. The focus on improving patient outcomes, reducing hospitalizations, and managing chronic GI conditions more effectively is fueling the expansion of gastrointestinal therapeutics.

Overall, the increasing prevalence of gastrointestinal diseases, the growing demand for biologic and personalized therapies, and ongoing advancements in medical technology are driving the robust growth of the gastrointestinal therapeutics market. As healthcare continues to focus on improving the quality of life for patients with digestive disorders, the demand for innovative and effective treatments will continue to rise.

SCOPE OF STUDY:

The report analyzes the Gastrointestinal Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

End-Use (Crohn's Disease, Ulcerative Colitis, GERD, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie, Inc.
• Alfa Wassermann, Inc.
• Allergan PLC
• Amgen, Inc.
• Anterogen Co., Ltd.
• Ardelyx, Inc.
• Astellas Pharma, Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Biogen, Inc.
• Celgene Corporation
• Cosmo Pharmaceuticals NV
• Drais Pharmaceuticals, Inc.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Enlivex Therapeutics ltd.
• F. Hoffmann-La Roche AG
• Ferring Pharmaceuticals, Inc.
• FF Pharma
• Galapagos NV
• Gilead Sciences, Inc.
• GlaxoSmithKline, Inc.
• Hutchison MediPharma Limited
• Immune Pharmaceuticals, Inc.
• InDex Pharmaceuticals Holding AB
• Ironwood Pharmaceuticals, Inc.
• Johnson & Johnson
• Kissei Pharmaceutical Co., Ltd.
• Kyowa Hakko Kirin Co., Ltd.
• Lexicon Pharmaceuticals, Inc.
• Lipid Therapeutics GmbH
• Meda AB
• Merck & Co., Inc.
• Mesoblast Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Mochida Pharmaceutical Co., Ltd.
• Morphotek, Inc.
• Neovacs S.A.
• Nestle SA
• Norgine BV
• Novartis AG
• Pfizer, Inc.
• Procter & Gamble Company, The
• Qu Biologics Inc.
• RedHill Biopharma Ltd.
• Sterna Biologicals GmbH & Co. KG
• Synthetic Biologics, Inc.
• Takeda Pharmaceutical Co., Ltd.
• TiGenix NV
• Tillotts Pharma AG
• TopiVert Ltd.
• UCB SA

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • Global Economic Update
  • Gastrointestinal Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Gastrointestinal Disorders Globally Drives Demand for Therapeutics
  • Increasing Adoption of Biologics in Treating Inflammatory Bowel Diseases Propels Market Growth
  • Expanding Elderly Population and Associated Gastrointestinal Complications Boost Drug Demand
  • Advances in Diagnostic Techniques Improve Early Detection and Treatment Opportunities
  • Role of Microbiome Therapeutics in Revolutionizing GI Treatment Paradigms
  • Integration of Alternative and Complementary Medicines in Treatment Regimens
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gastrointestinal Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gastrointestinal Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Crohn's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Crohn's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Crohn's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Ulcerative Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for GERD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for GERD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for GERD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 17: USA Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 18: USA Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: USA 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: Canada Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: Canada 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 23: Japan Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 24: Japan Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: Japan 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 26: China Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: China Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: China 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Gastrointestinal Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: Europe 15-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Europe Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: Europe 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 35: France Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: France Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: France 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 38: Germany Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Germany Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Germany 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 41: Italy Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Italy Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Italy 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 44: UK Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: UK Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: UK 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 47: Spain Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Spain Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Spain 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 50: Russia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Russia Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Russia 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Rest of Europe Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Rest of Europe 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: Asia-Pacific Historic Review for Gastrointestinal Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Asia-Pacific 15-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Asia-Pacific Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Asia-Pacific 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 62: Australia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Australia Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Australia 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 65: India Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: India Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: India 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 68: South Korea Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: South Korea Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: South Korea 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Rest of Asia-Pacific Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Rest of Asia-Pacific 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 74: Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Latin America Historic Review for Gastrointestinal Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Latin America 15-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 77: Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Latin America Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Latin America 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 80: Argentina Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Argentina Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Argentina 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 83: Brazil Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Brazil Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Brazil 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 86: Mexico Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Mexico Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Mexico 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Rest of Latin America Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Rest of Latin America 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 92: Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 93: Middle East Historic Review for Gastrointestinal Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Middle East 15-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 95: Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Middle East Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Middle East 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 98: Iran Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Iran Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Iran 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 101: Israel Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Israel Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Israel 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Saudi Arabia Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Saudi Arabia 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 107: UAE Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UAE Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UAE 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Rest of Middle East Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Rest of Middle East 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 113: Africa Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Africa Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Africa 15-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn's Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION